SEC Form 424B5 filed by Celldex Therapeutics Inc.
(To Prospectus dated November 3, 2023)
| | | |
PER SHARE
|
| |
TOTAL
|
| ||||||
|
Public offering price
|
| | | $ | 47.00 | | | | | $ | 400,440,000 | | |
|
Underwriting discounts and commissions(1)
|
| | | $ | 2.82 | | | | | $ | 24,026,400 | | |
|
Proceeds to us, before expenses
|
| | | $ | 44.18 | | | | | $ | 376,413,600 | | |
|
Leerink Partners
|
| |
TD Cowen
|
| |
Guggenheim Securities
|
| |
Cantor
|
|
|
LifeSci Capital
|
| |
H.C. Wainwright & Co.
|
|
| | | |
PAGE
|
| |||
| Prospectus Supplement | | | | | | | |
| | | | | S-1 | | | |
| | | | | S-3 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-11 | | | |
| | | | | S-16 | | | |
| | | | | S-16 | | | |
| | | | | S-16 | | | |
| | | | | S-17 | | | |
| Prospectus | | | | | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 18 | | |
this prospectus supplement
and for general corporate purposes. See “Use of Proceeds” on page S-9 of this prospectus supplement.
|
Public offering price per share
|
| | | | | | | | | $ | 47.00 | | |
|
Net tangible book value per share as of December 31, 2023
|
| | | $ | 7.19 | | | | | | | | |
|
Increase in net tangible book value per share attributable to the offering
|
| | | | 4.89 | | | | | | | | |
|
As adjusted net tangible book value per share after giving effect to
the offering |
| | | | | | | | | | 12.08 | | |
|
Dilution in net tangible book value per share to new investors
|
| | | | | | | | | $ | 34.92 | | |
Underwriter
|
| |
NUMBER OF
SHARES |
| |||
Leerink Partners LLC
|
| | | | 2,641,200 | | |
Cowen and Company, LLC
|
| | | | 2,641,200 | | |
Guggenheim Securities, LLC.
|
| | | | 1,192,800 | | |
Cantor Fitzgerald & Co.
|
| | | | 1,192,800 | | |
LifeSci Capital LLC.
|
| | | | 681,600 | | |
H.C. Wainwright & Co., LLC
|
| | | | 170,400 | | |
Total
|
| | | | 8,520,000 | | |
| | | | | | | | |
TOTAL
|
| |||||||||
| | |
Per
Share |
| |
Without
Option |
| |
With
Option |
| |||||||||
Initial public offering price
|
| | | $ | 47.00 | | | | | $ | 400,440,000 | | | | | $ | 460,506,000 | | |
Underwriting discounts and commissions
|
| | | $ | 2.82 | | | | | $ | 24,026,400 | | | | | $ | 27,630,360 | | |
Proceeds, before expenses, to us
|
| | | $ | 44.18 | | | | | $ | 376,413,600 | | | | | $ | 432,875,640 | | |
Celldex Therapeutics, Inc.
Perryville III Building, 53 Frontage Road, Suite 220,
Hampton, New Jersey 08827
(908) 200-7500
Preferred Stock
Warrants
Depositary Shares
Units
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 11 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 17 | | | |
| | | | 18 | | |
Celldex Therapeutics, Inc.
Perryville III Building, 53 Frontage Road, Suite 220,
Hampton, New Jersey 08827
(908) 200-7500
|
Leerink Partners
|
| |
TD Cowen
|
| |
Guggenheim Securities
|
| |
Cantor
|
|
|
LifeSci Capital
|
| |
H.C. Wainwright & Co.
|
|